Navigation Links
Bionovo Announces 2011 Highlights and Year-End Financial Results
Date:3/30/2012

hese shares against the full amount owed to the Company under the note.  On February 29, 2012, the Socius Purchase Agreement terminated pursuant to its terms.  The gross proceeds received from Socius were $1,050,000.
  • On February 2, 2011, the Company closed a follow-on stock offering, with net proceeds of $27.2 million. The financing was underwritten by Cowen and Company.

  • Full Year ResultsFor the year ended December 31, 2011 total revenues were $0.3 million compared with $0.6 million for the same period in 2010. Revenues in 2011 consisted of $0.3 million in a National Institute of Health (NIH) grant. Revenues in 2010 consisted of a Qualifying Therapeutic Discovery Project Credit of $0.5 million and $0.1 million in a National Institute of Health (NIH) grant.

    For the year ended December 31, 2011 total operating expenses were $23.9 million compared with $18.2 million for the same period in 2010. The increase in 2011 operating expenses is primarily due to completion of Menerba tolerability studies, initiation of the Menerba Phase 3 clinical study and manufacturing costs at our Hayward, California manufacturing facility, partially offset by no employee or officer bonuses for 2011.

    The net loss for the year ended December 31, 2011 was $13.7 million, or $0.26 per share, compared with a net loss of $17.7 million, or $0.80 per share, for the same period in 2010. The year-over-year decrease in net loss was driven primarily by change in fair value of the warrant liability offset by increased operating expenses as noted above.

    As of December 31, 2011, cash, cash equivalents and short-term investments totaled approximately $3.0 million compared to $2.6 million at December 31, 2010. The decrease is due to cash used in operating activities of $17.6 million and cash used in investing activities of $8.5 million offset by the net cash provided from financing acti
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
    2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
    3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
    4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
    5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
    6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
    7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
    8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
    9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014  Nektar ... financial results for the third quarter ended September 30, ... of U.S.-based financial markets. Howard Robin , president ... to review the results beginning at 5:00 p.m. Eastern ... The press release and a live audio-only Webcast of ...
    (Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
    (Date:10/30/2014)... 2014  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced an upcoming presentation highlighting ... aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind Covalently ... by Sant P. Chawla , M.D., F.R.A.C.P., ... investigator of the Company,s ongoing global, pivotal Phase ...
    Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2China Biologic to Report Third Quarter 2014 Financial Results 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
    (Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
    (Date:10/30/2014)... Don Allred Insurance, a leading provider of home, ... Carolina residents, is excited to announce the Grand Opening ... The new branch has been up and running since ... facets of the insurance selection process from quote comparison ... couldn’t be happier with the timing of this Grand ...
    (Date:10/30/2014)... October 30, 2014 Radio listeners who ... questions about the impact of traditional radio commercials and ... most likely to influence a purchasing decision. , Those ... 525 consumers conducted by radio marketing company CRN International. ... isolating the results of respondents who indicated they have ...
    (Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
    (Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
    Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
    ... YORK, Nov. 1 Fibromyalgia is the most ... affecting more than,six million Americans. But, findings from ... (NFA) show there is still much to be,learned ... the general public shows nearly half (45%) of ...
    ... Nov. 1 Always Best Care Senior,Services has expanded ... Service, and Personal Response Company, is proud,to announce seniors ... Senior,Services for outstanding care. For over a decade, a ... a sincere concern for the betterment of,life that goes ...
    ... Medicare plans in 90 cities will,be recognized ... their 2008 medical,and Part D prescription drug benefits ... were selected from over 200 Medicare Advantage,managed care ... HealthMetrix Research Inc. and MedicareNewsWatch.com. According,to HealthMetrix Research ...
    ... the current issue of Clinical Pharmacology & Therapeutics, ... Bioethics and Johns Hopkins Berman Institute of Bioethics ... vaccine debate, and its effects on ethical and ... was a major achievement for cervical cancer prevention ...
    ... Medical School (UMMS) will investigate the causes of type ... Research Foundation (JDRF) and The Iacocca Foundation. The grants, ... the UMMS Heat Shock Protein Consortium. Directed by Aldo ... of Medicine and professor of medicine and molecular medicine, ...
    ... 100th year of advancing cancer research, the American Association ... America, Europe, and Asia. The AACR has teamed ... for Science, Technology and Research (A*STAR) to hold the ... in Singapore: the AACR Centennial Conference on Translational Cancer ...
    Cached Medicine News:Health News:Medialink Features: The Painful Truth About Fibromyalgia 2Health News:Announcing Always Best Care Senior Services Expansion Into Cleveland, Ohio 2Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 2Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 3Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 4Health News:A missed shot: The failure of HPV vaccination state requirements 2Health News:A missed shot: The failure of HPV vaccination state requirements 3Health News:UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation 2Health News:Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference 2
    ... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
    ... Aircast VenaFlow System (a prophylaxis for DVT), ... styles: calf, foot, and thigh, to suit ... from light, cool, comfortable material to promote ... be placed directly against the skin. With ...
    ... A new cast boot specially ... on a double rocker sole for ... built around a narrow last so ... plaster cast boots, and with our ...
    This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
    Medicine Products: